Mediwound Ltd
MDWD18.070USD
-0.460-2.48%
Market hours （ET）Quotes delayed by 15 min
203.32MMarket Cap
LossP/E TTM
More Details of Mediwound Ltd Company
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Company Info
Ticker SymbolMDWD
Company nameMediwound Ltd
IPO dateMar 20, 2014
CEOMr. Ofer Gonen
Number of employees111
Security typeOrdinary Share
Fiscal year-endMar 20
Address42 Hayarkon Street
CityYAVNE
Stock exchangeNASDAQ Global Market Consolidated
CountryIsrael
Postal code8122745
Phone972779714100
Websitehttps://www.mediwound.com/
Ticker SymbolMDWD
IPO dateMar 20, 2014
CEOMr. Ofer Gonen
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Dr. Robert J. Snyder
Dr. Robert J. Snyder
Chief Medical Officer
Chief Medical Officer
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+84.44%
Mr. Nachum (Homi) Shamir
Mr. Nachum (Homi) Shamir
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
13.71%
Investor AB
8.07%
Yelin Lapidot Provident Funds Management Ltd
7.94%
Rosalind Advisors, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
61.58%
Shareholders
Shareholders
Proportion
Clal Biotechnology Industries Ltd
13.71%
Investor AB
8.07%
Yelin Lapidot Provident Funds Management Ltd
7.94%
Rosalind Advisors, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
61.58%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.44%
Holding Company
13.71%
Private Equity
8.07%
Hedge Fund
6.43%
Investment Advisor/Hedge Fund
4.48%
Venture Capital
3.50%
Corporation
2.57%
Individual Investor
1.68%
Research Firm
0.59%
Other
38.51%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
127
6.76M
62.53%
-1.01M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
2023Q2
64
5.23M
72.67%
+954.42K
2023Q1
68
5.13M
65.71%
+1.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clal Biotechnology Industries Ltd
1.48M
13.71%
--
--
Mar 15, 2025
Investor AB
872.09K
8.07%
--
--
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
858.00K
7.94%
+6.64K
+0.78%
Mar 31, 2025
Rosalind Advisors, Inc.
506.89K
4.69%
-121.16K
-19.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
434.00K
4.02%
+34.17K
+8.55%
Mar 31, 2025
Israel Biotech Fund
378.62K
3.5%
-172.63K
-31.32%
Mar 15, 2025
Deep Insight Limited Partnership
278.18K
2.57%
-273.07K
-49.54%
Mar 15, 2025
Gonen (Ofer)
182.10K
1.68%
+83.37K
+84.44%
Mar 15, 2025
T. Rowe Price Associates, Inc.
154.95K
1.43%
+150.56K
+3429.70%
Mar 31, 2025
Essex Investment Management Company, LLC
147.87K
1.37%
-1.08K
-0.73%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Israel Innovative Technology ETF
1.58%
Invesco NASDAQ Future Gen 200 ETF
0.4%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ARK Israel Innovative Technology ETF
Proportion1.58%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.4%
iShares Micro-Cap ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Date
Type
Ratio
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
Dec 19, 2022
Merger
7<1
